The earnings miss may pressure the stock near-term, but positive clinical data and strong cash runway support the pipeline narrative. Watch for initiation of the Himalayas-1 Phase 3 trial in 1H 2026 and multiple data readouts in 2H 2026.
Price Chart
Executive Summary
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.7%, as R&D spending increased to $31.4M. However, the company announced selection of rinzimetostat RP3D and positive clinical data, with cash of $419.7M funding operations into 2H 2028.
Key Financial Metrics
Key Facts
- Net loss per share $(0.34) vs consensus $(0.31) (EPS miss of ~9.7%)
- Q1 2026 net loss $35.8M vs $30.0M in Q1 2025, driven by higher R&D costs
- Cash, cash equivalents and investments $419.7M as of March 31, 2026
- R&D expenses $31.4M, up 27.5% YoY due to advancement of rinzimetostat and enozertinib
- Selected rinzimetostat 400 mg once daily as RP3D for Himalayas-1 Phase 3 trial in post-abiraterone mCRPC
- Positive rinzimetostat data showing landmark rPFS rates superior to standard of care
- Initiation of first Phase 3 registrational trial expected in 1H 2026
Financial Impact
EPS miss of $0.03 (9.7%) vs consensus; higher net loss due to increased R&D spending
Risk Factors
- EPS miss and higher net loss could disappoint short-term traders
- Clinical trial risks, including potential delays or negative data
- Dilution risk from continued ATM offerings (raised $59.9M in Q1 2026)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-203993 |
| Document: oric-20260504.htm | 0001193125-26-203993 |
| Document: 0001193125-26-203993-index-headers.html | 0001193125-26-203993 |
| Document: 0001193125-26-203993-index.html | 0001193125-26-203993 |
| Document: 0001193125-26-203993.txt | 0001193125-26-203993 |
| 8-K Data (Synthetic) | 0001193125-26-203993 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 8w ago | Press Release | $13.47 $12.89 | ▼ −4.31% | ▼ −3.07% | $12.23 (−9.21%) |
Jun 22, 2026 14w ago | 8-K | $8.91 $10.42 | ▲ +16.95% | ▲ +15.79% | $12.23 (+37.26%) |
Jun 11, 2026 16w ago | Institutional Cluster | $7.82 $10.94 | ▲ +39.90% | ▲ +38.01% | $12.23 (+56.39%) |
May 4, 2026 21w ago | 8-K | $9.57 $7.62 | ▼ −20.38% | ▼ −25.33% | $12.23 (+27.80%) |
Apr 3, 2026 25w ago | Press Release | $8.91 $9.63 | ▲ +8.08% | ▼ −0.90% | $12.23 (+37.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access